UniClo: scarless hierarchical DNA assembly without sequence constraint
- PMID: 40548934
- PMCID: PMC12205989
- DOI: 10.1093/nar/gkaf548
UniClo: scarless hierarchical DNA assembly without sequence constraint
Abstract
Type IIS restriction enzyme-mediated DNA assembly is efficient but has sequence constraints and can result in unwanted sequence scars. To overcome these drawbacks, we developed UniClo, a type IIS restriction enzyme-mediated method for universal and flexible DNA assembly. This is achieved through a combination of vector engineering, DNA methylation using recombinant methylases, and steric blockade using CRISPR-dCas9 technology to regulate this methylation. Type IIS restriction enzyme sites within fragments to be assembled are methylated using recombinant methylases, while the fragment-flanking outer sites are protected from methylation by a recombinant dCas9-sgRNA complex. During the subsequent assembly reaction, only the protected flanking sites are cut as only they are unmethylated. Fragments are correctly assembled, despite containing internal sites for the single type IIS restriction enzyme used for the one-pot assembly. The assembled plasmid can be used as a donor plasmid in a subsequent assembly round with the same type IIS restriction enzyme and the assembly vector engineering ensures removal of potential scars by a trimming process. This simplifies assembly design and only three vectors are required for any multi-round assembly. These vectors all use the same pair of overhangs. UniClo provides a simple scarless approach for hierarchical assembly of any sequence and has wide potential application.
© The Author(s) 2025. Published by Oxford University Press on behalf of Nucleic Acids Research.
Conflict of interest statement
D.L., K.R., and C.A.O’C. are named as inventors on patent applications related to this work (PCT/GB2018/051174 and PCT/EP2020/059420). D.L. is a cofounder of Triple Helix Biotechnology Ltd., which has financial interests in these patent applications.
Figures










Similar articles
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
-
Advanced viral genome in vitro Cas9 editing (AdVICE): an overnight method for traceless and limitless manipulation of adenoviral and vector genomes with large transgenes.J Virol. 2025 Jun 17;99(6):e0226524. doi: 10.1128/jvi.02265-24. Epub 2025 May 21. J Virol. 2025. PMID: 40396759 Free PMC article.
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
-
Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature.Health Technol Assess. 2001;5(26):1-149. doi: 10.3310/hta5260. Health Technol Assess. 2001. PMID: 11701099
-
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2. Cochrane Database Syst Rev. 2020. PMID: 33075160 Free PMC article.
References
-
- Engler C, Marillonnet S. Polizzi KM, Kontoravdi C Combinatorial DNA assembly using golden gate cloning. Synthetic Biology. 2013; 1073:New York: Springer Science+Business Media; 141–56. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials